|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM11 |
Gene summary for TRIM11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM11 | Gene ID | 81559 |
| Gene name | tripartite motif containing 11 | |
| Gene Alias | BIA1 | |
| Cytomap | 1q42.13 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q96F44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81559 | TRIM11 | LZE7T | Human | Esophagus | ESCC | 4.35e-07 | 2.01e-01 | 0.0667 |
| 81559 | TRIM11 | LZE20T | Human | Esophagus | ESCC | 1.09e-07 | 1.95e-01 | 0.0662 |
| 81559 | TRIM11 | LZE21D1 | Human | Esophagus | HGIN | 1.49e-02 | 1.98e-01 | 0.0632 |
| 81559 | TRIM11 | LZE24T | Human | Esophagus | ESCC | 4.30e-09 | 3.32e-01 | 0.0596 |
| 81559 | TRIM11 | LZE22D3 | Human | Esophagus | HGIN | 4.34e-02 | 3.75e-01 | 0.0653 |
| 81559 | TRIM11 | LZE21T | Human | Esophagus | ESCC | 1.98e-02 | 2.78e-01 | 0.0655 |
| 81559 | TRIM11 | P1T-E | Human | Esophagus | ESCC | 1.99e-10 | 5.34e-01 | 0.0875 |
| 81559 | TRIM11 | P2T-E | Human | Esophagus | ESCC | 6.69e-20 | 2.76e-01 | 0.1177 |
| 81559 | TRIM11 | P4T-E | Human | Esophagus | ESCC | 6.84e-08 | 1.44e-01 | 0.1323 |
| 81559 | TRIM11 | P5T-E | Human | Esophagus | ESCC | 9.50e-18 | 3.65e-01 | 0.1327 |
| 81559 | TRIM11 | P8T-E | Human | Esophagus | ESCC | 1.98e-13 | 1.58e-01 | 0.0889 |
| 81559 | TRIM11 | P9T-E | Human | Esophagus | ESCC | 6.06e-13 | 2.31e-01 | 0.1131 |
| 81559 | TRIM11 | P10T-E | Human | Esophagus | ESCC | 1.11e-19 | 2.23e-01 | 0.116 |
| 81559 | TRIM11 | P11T-E | Human | Esophagus | ESCC | 1.92e-06 | 3.10e-01 | 0.1426 |
| 81559 | TRIM11 | P12T-E | Human | Esophagus | ESCC | 9.70e-14 | 2.06e-01 | 0.1122 |
| 81559 | TRIM11 | P15T-E | Human | Esophagus | ESCC | 1.69e-20 | 5.00e-01 | 0.1149 |
| 81559 | TRIM11 | P16T-E | Human | Esophagus | ESCC | 3.82e-08 | 2.26e-01 | 0.1153 |
| 81559 | TRIM11 | P17T-E | Human | Esophagus | ESCC | 5.87e-04 | 2.78e-01 | 0.1278 |
| 81559 | TRIM11 | P20T-E | Human | Esophagus | ESCC | 1.65e-14 | 3.62e-01 | 0.1124 |
| 81559 | TRIM11 | P21T-E | Human | Esophagus | ESCC | 1.05e-20 | 3.35e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
| GO:001905827 | Esophagus | HGIN | viral life cycle | 93/2587 | 317/18723 | 3.66e-13 | 5.63e-11 | 93 |
| GO:005079225 | Esophagus | HGIN | regulation of viral process | 50/2587 | 164/18723 | 2.53e-08 | 1.49e-06 | 50 |
| GO:190390025 | Esophagus | HGIN | regulation of viral life cycle | 45/2587 | 148/18723 | 1.36e-07 | 6.78e-06 | 45 |
| GO:004852419 | Esophagus | HGIN | positive regulation of viral process | 25/2587 | 65/18723 | 6.88e-07 | 2.95e-05 | 25 |
| GO:004440326 | Esophagus | HGIN | biological process involved in symbiotic interaction | 71/2587 | 290/18723 | 7.09e-07 | 3.00e-05 | 71 |
| GO:005170127 | Esophagus | HGIN | biological process involved in interaction with host | 51/2587 | 203/18723 | 1.16e-05 | 3.29e-04 | 51 |
| GO:001908016 | Esophagus | HGIN | viral gene expression | 28/2587 | 94/18723 | 4.52e-05 | 1.09e-03 | 28 |
| GO:005212627 | Esophagus | HGIN | movement in host environment | 43/2587 | 175/18723 | 9.45e-05 | 2.03e-03 | 43 |
| GO:190390210 | Esophagus | HGIN | positive regulation of viral life cycle | 12/2587 | 29/18723 | 2.48e-04 | 4.38e-03 | 12 |
| GO:004852510 | Esophagus | HGIN | negative regulation of viral process | 25/2587 | 92/18723 | 5.41e-04 | 7.71e-03 | 25 |
| GO:004390320 | Esophagus | HGIN | regulation of biological process involved in symbiotic interaction | 20/2587 | 72/18723 | 1.39e-03 | 1.63e-02 | 20 |
| GO:004659815 | Esophagus | HGIN | positive regulation of viral entry into host cell | 6/2587 | 11/18723 | 1.71e-03 | 1.86e-02 | 6 |
| GO:007529415 | Esophagus | HGIN | positive regulation by symbiont of entry into host | 6/2587 | 11/18723 | 1.71e-03 | 1.86e-02 | 6 |
| GO:00190834 | Esophagus | HGIN | viral transcription | 15/2587 | 50/18723 | 2.35e-03 | 2.39e-02 | 15 |
| GO:004440927 | Esophagus | HGIN | entry into host | 34/2587 | 151/18723 | 2.43e-03 | 2.43e-02 | 34 |
| GO:000961517 | Esophagus | HGIN | response to virus | 69/2587 | 367/18723 | 4.39e-03 | 3.86e-02 | 69 |
| GO:00190766 | Esophagus | HGIN | viral release from host cell | 11/2587 | 34/18723 | 4.61e-03 | 3.96e-02 | 11 |
| GO:00358906 | Esophagus | HGIN | exit from host | 11/2587 | 34/18723 | 4.61e-03 | 3.96e-02 | 11 |
| GO:00358916 | Esophagus | HGIN | exit from host cell | 11/2587 | 34/18723 | 4.61e-03 | 3.96e-02 | 11 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM11 | SNV | Missense_Mutation | novel | c.970C>T | p.Arg324Cys | p.R324C | Q96F44 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TRIM11 | SNV | Missense_Mutation | rs370800532 | c.1291G>A | p.Glu431Lys | p.E431K | Q96F44 | protein_coding | deleterious(0.04) | benign(0.111) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| TRIM11 | SNV | Missense_Mutation | rs753855545 | c.1304N>T | p.Ser435Leu | p.S435L | Q96F44 | protein_coding | tolerated(0.06) | possibly_damaging(0.828) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM11 | SNV | Missense_Mutation | c.1126N>A | p.Gly376Ser | p.G376S | Q96F44 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM11 | SNV | Missense_Mutation | novel | c.650A>G | p.His217Arg | p.H217R | Q96F44 | protein_coding | tolerated(0.94) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TRIM11 | SNV | Missense_Mutation | rs752798123 | c.550N>T | p.Arg184Cys | p.R184C | Q96F44 | protein_coding | deleterious(0) | possibly_damaging(0.676) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM11 | SNV | Missense_Mutation | c.982G>T | p.Gly328Cys | p.G328C | Q96F44 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
| TRIM11 | SNV | Missense_Mutation | c.1375N>T | p.Gly459Cys | p.G459C | Q96F44 | protein_coding | deleterious(0.04) | probably_damaging(0.92) | TCGA-BS-A0U7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM11 | SNV | Missense_Mutation | c.1126N>A | p.Gly376Ser | p.G376S | Q96F44 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM11 | SNV | Missense_Mutation | novel | c.809G>T | p.Arg270Met | p.R270M | Q96F44 | protein_coding | deleterious(0) | benign(0.438) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |